Johnson & Johnson has submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of its COVID-19 vaccine in India in adolescents aged 12-17 years," news agency ANI tweeted.
Johnson & Johnson has submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of its COVID-19 vaccine in India in adolescents aged 12-17 years.
The single-shot vaccine, developed by J&J shown to be 85 per cent efficacy in preventing severe disease in Phase 3 human clinical trials.
Earlier in August, J&J informed had pplied for Emergency Use Authorization (EUA) of its single-dose COVID-19 vaccine Janssen in India.